# Kanvas Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kanvas-biosciences

- Industry: Biotechnology
- Headquarters: Monmouth, US
- Website: www.kanvasbio.com/
- Total disclosed funding: $61M
- Latest round: Series A (May 6, 2026)
- Investors on record: 19

## About

Kanvas Biosciences, Inc. is a US-based company focused on developing live biotherapeutics to enhance health outcomes by modulating the human microbiome through advanced spatial biology technology. 

Kanvas Biosciences, Inc., founded in 2020 and headquartered in Monmouth, US, specializes in developing biotherapeutics targeting the human microbiome. The company was established by Matthew Cheng who is also the CEO, Hao Shi who is also the CTO. In June 2026, Kanvas Biosciences, Inc. raised an undisclosed amount of venture funding from Zeon Ventures. 

Kanvas Biosciences specializes in developing live biotherapeutics aimed at modulating the human microbiome to enhance health outcomes. Their innovative full-stack technology platform integrates spatial mapping and discovery engines, providing detailed insights into the interactions between the host and microbiome. This advanced approach has enabled Kanvas to translate these insights into scalable and reproducible clinical-stage therapies designed to precisely modulate host immunity. Targeted primarily at healthcare providers and research institutions, their product offerings focus on applications in various health conditions, particularly those involving immune modulation. The company’s services and products are marketed across North America and Europe, addressing a diverse clientele that includes hospitals, clinical research organizations, and biotechnology firms engaged in microbiome research.

Kanvas Biosciences operates on a business model involving partnerships with healthcare institutions and various stakeholders in the biotechnology sector. Revenue is generated through collaborative agreements, which may involve providing live biotherapeutics for clinical trials or research purposes. Transactions between Kanvas and its clients are structured around direct collaborations where healthcare providers might sponsor research or acquire therapeutic products for patient treatment. The company’s flagship products, designed for specific therapeutic applications, are anticipated to be provided under subscription agreements or as part of licensing arrangements. While specific pricing structures for these offerings are not disclosed, the financial transactions are expected to align with the industry standards for biotherapeutics, reflecting the value of the unique biological insights and therapeutic innovations that Kanvas provides to its partners and clients. 

Kanvas Biosciences is expected to use the funding to advance its microbiome drug discovery and manufacturing platform, accelerate clinical development of live biotherapeutics, and expand partnerships in biotechnology and pharmaceutical ecosystems. For Zeon, the investment provides exposure to emerging microbiome therapeutics and supports long-term growth in healthcare and life sciences as part of its strategic portfolio expansion.

## Funding rounds

- Series A, May 6, 2026, $48M — Cornell University Endowment, Gates Foundation Trust, Rochester Institute of Technology Endowment, Pangaea Ventures, DCVC, Alumni Ventures Group, Gaingels, Athos Capital, Uncommon Denominator, Germin8 Ventures, Mana Ventures, FemHealth Ventures, Boutique Venture Partners, Triple Impact Capital, Kicker Ventures, Red Beard Ventures, Ki Tua Fund, Lions Capital
- Seed, Jul 1, 2024, $13M — Pangaea Ventures, DCVC, Lions Capital Partner, Germin8 Ventures, FemHealth Ventures, Ki Tua Fund

## Investors

- Pangaea Ventures (https://capitalatlas.ai/funds/pangaea-ventures) — Seed, Series A
- DCVC (https://capitalatlas.ai/funds/dcvc) — Seed, Series A
- Lions Capital Partner — Seed
- Germin8 Ventures (https://capitalatlas.ai/funds/germin8-ventures) — Seed, Series A
- FemHealth Ventures (https://capitalatlas.ai/funds/femhealth-ventures) — Seed, Series A
- Ki Tua Fund (https://capitalatlas.ai/funds/ki-tua-fund) — Seed, Series A
- Cornell University Endowment — Series A
- Gates Foundation Trust — Series A
- Rochester Institute of Technology Endowment — Series A
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series A
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series A
- Athos Capital (https://capitalatlas.ai/funds/athos-capital) — Series A
- Uncommon Denominator (https://capitalatlas.ai/funds/uncommon-denominator) — Series A
- Mana Ventures (https://capitalatlas.ai/funds/mana-ventures) — Series A
- Boutique Venture Partners (https://capitalatlas.ai/funds/boutique-venture-partners) — Series A
- Triple Impact Capital (https://capitalatlas.ai/funds/triple-impact-capital) — Series A
- Kicker Ventures (https://capitalatlas.ai/funds/kicker-ventures) — Series A
- Red Beard Ventures (https://capitalatlas.ai/funds/red-beard-ventures) — Series A
- Lions Capital (https://capitalatlas.ai/funds/lions-capital) — Series A